Literature DB >> 1674474

Alpha 2-adrenoceptors inhibit a nociceptive response in neonatal rat spinal cord.

J J Kendig1, M K Savola, S J Woodley, M Maze.   

Abstract

Alpha 2-Adrenoceptors mediate analgesia in vivo. The present study explored the actions of the alpha 2-adrenoceptor agonists dexmedetomidine and clonidine on a nociceptive response in isolated neonatal rat spinal cord. Stimulation of a dorsal root generates a slow ventral root potential (slow VRP) at the corresponding ipsilateral ventral root. The slow VRP meets several criteria for a nociceptive response. Dexmedetomidine (10 nM) and clonidine (200 nM) depressed the slow VRP by approximately 80%. Dexmedetomidine's action was approximately linear over the concentration range 0.5-500 nM, whereas clonidine (20 nM-5 microM) exerted biphasic effects. The profile of agonist and antagonist effectiveness characterized the receptor(s) as alpha 2-adrenoceptors; the subtype could not be identified as either alpha 2A or alpha 2B. Naloxone pretreatment partially blocked dexmedetomidine's effect, suggesting a possible endogenous opiate involvement. Dexmedetomidine (0.5-2.0 nM) also depressed the VRP evoked by application of substance P to the cord, implicating postsynaptic as well as possible presynaptic actions. At high concentrations, dexmedetomidine (50-500 nM) depressed the monosynaptic reflex, probably through non-alpha 2-receptor(s). Results from the neonatal spinal cord correlate well with those from in vivo analgesia studies. They suggest an important direct spinal contribution to alpha 2-adrenoceptor-mediated analgesia.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674474     DOI: 10.1016/0014-2999(91)90055-u

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Inhibitory effects of dopamine on spinal synaptic transmission via dopamine D1-like receptors in neonatal rats.

Authors:  K Kawamoto; K Otsuguro; M Ishizuka; S Ito
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Preweanling naltrindole administration differentially affects clonidine induced antinociception and plasma adrenaline levels in male and female neonatal rats.

Authors:  I Alberti; B Fernández; L F Alguacil; A Aguilar; M Caamaño; E M Romero; M P Viveros
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Inhibitory effects of eugenol on putative nociceptive response in spinal cord preparation isolated from neonatal rats.

Authors:  Saki Yagura; Hiroshi Onimaru; Koji Kanzaki; Masahiko Izumizaki
Journal:  Exp Brain Res       Date:  2018-04-13       Impact factor: 1.972

4.  Effects of spinal naloxone and naltrindole on the antinociceptive action of intrathecally administered dexmedetomidine.

Authors:  Y Takano; M Takano; I Sato; T L Yaksh
Journal:  J Anesth       Date:  1996-09       Impact factor: 2.078

5.  The pharmacology of descending responses evoked by thoracic stimulation in the neonatal rat spinal cord in vitro.

Authors:  D I Wallis; J Wu
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-06       Impact factor: 3.000

6.  The effect of centrally acting myorelaxants on NMDA receptor-mediated synaptic transmission in the immature rat spinal cord in vitro.

Authors:  R J Siarey; S K Long; R H Evans
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

7.  [Antinociceptive effects of alpha(2)-adrenoceptor agonists ("analgesic" actions in animal experiments)agonists ("analgesic" actions in animal experiments).].

Authors:  I Jurna
Journal:  Schmerz       Date:  1995-11       Impact factor: 1.107

8.  Evaluation of antinociceptive and neurotoxic effects of intrathecal dexmedetomidine in rats.

Authors:  Ozgü Işgüzar; Sibel Barış; Ayhan Bozkurt; Bilge Can; Sırrı Bilge; Hatice Türe
Journal:  Balkan Med J       Date:  2012-12-01       Impact factor: 2.021

9.  Characterization of spinal alpha-adrenergic modulation of nociceptive transmission and hyperalgesia throughout postnatal development in rats.

Authors:  S M Walker; M Fitzgerald
Journal:  Br J Pharmacol       Date:  2007-05-29       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.